<DOC>
	<DOCNO>NCT01283386</DOCNO>
	<brief_summary>This multi-center , randomize study compare efficacy safety MabThera ( rituximab ) combination either fludarabine cyclophosphamide chlorambucil patient previously untreated B-cell chronic lymphocytic leukemia unfavourable somatic status . Patients randomize receive Mabthera ( 375 mg/m2 intravenously [ iv ] Day 1 Cycle 1 , 500 mg/m2 iv Day 1 Cycles 2-6 ) either fludarabine ( 20 mg/m2 iv 32 mg/m2 orally Days 1-3 ) cyclophosphamide ( 150 mg/m2 iv orally Days 1-3 ) chlorambucil ( 10 mg/m2 orally Days 1-7 ) 6 cycle 28 day . Anticipated time study treatment 24 week .</brief_summary>
	<brief_title>A Study Compare Mabthera ( Rituximab ) , Fludarabine Cyclophosphamide Mabthera Chlorambucil Patients With Chronic Lymphocytic Leukemia Unfavourable Somatic Status</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Adult patient , 6070 &gt; 70 year age Cumulative Illness Rating Scale ( CIRS ) comorbidity score &gt; /=7 patient 6070 year old Previously untreated Bcell chronic lymphocytic leukemia Binet stage B , C A progression ECOG performance status 02 Smallcell lymphoma Autoimmune hemolytic anemia Concomitant malignant disease enrollment , except basal cell carcinoma skin Chemotherapy concomitant malignant disease within 12 month prior study enrollment Richter 's syndrome</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>